Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$119.10 USD

119.10
722,614

+0.60 (0.51%)

Updated Sep 4, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis Announces Positive Long-Term Data on Migraine Drug

by Zacks Equity Research

Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.

Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?

by Zacks Equity Research

Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.

FDA Grants Priority Review to Global Blood's SCD Candidate

by Zacks Equity Research

The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.

Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA

by Zacks Equity Research

The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs

by Kinjel Shah

Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.

AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC

by Zacks Equity Research

AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.

Why Novartis (NVS) Stock Might be a Great Pick

by Zacks Equity Research

Novartis (NVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Novartis Inks Commercialization Deal for Tysabri Biosimilar

by Zacks Equity Research

Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.

Global Blood Focuses on Lead Candidate Amid Competition

by Zacks Equity Research

Global Blood (GBT) focuses on the development of its lead product candidate, voxelotor - an oral, once-daily treatment for SCD.

5 Cancer-Fighting Stocks to Add to Your Portfolio

by Zacks Equity Research

Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.

Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry

by Zacks Equity Research

Shares of Glaxo (GSK) surpass the industry this year. Here are some reasons for the same.

AstraZeneca's Lupus Drug Meets Primary Endpoint in Study

by Zacks Equity Research

AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs

by Kinjel Shah

Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.

Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies

by Zacks Equity Research

Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.

Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer

by Zacks Equity Research

Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.

Kinjel Shah headshot

Forget Pfizer, Add These Big Drugmakers to Your Portfolio

by Kinjel Shah

Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.

Christopher Vargas headshot

J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?

by Christopher Vargas

An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.

Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo

by Zacks Equity Research

Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.

AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease

by Zacks Equity Research

AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.

Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis

by Zacks Equity Research

The FDA approves Eli Lilly's (LLY) Taltz injection for the treatment of adult patients with active ankylosing spondylitis. Shares rise.

Sweta Killa headshot

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

by Sweta Killa

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Has Novartis (NVS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVS) Outperforming Other Medical Stocks This Year?

Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study

by Zacks Equity Research

Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.

Novo Nordisk's Fiasp Gets EC Approval for Label Expansion

by Zacks Equity Research

Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.

Teva Launches Generic Version of Mylan's EpiPen for KIds

by Zacks Equity Research

Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.